Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04409431
Other study ID # AAA-S
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2019
Est. completion date June 1, 2023

Study information

Verified date May 2020
Source Third Military Medical University
Contact Li Yingsha, MD
Phone 13594659454
Email yslimiss@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary aldosteronism (PA) is one of the most common cause of endocrine and resistant hypertension. Current studies have shown that the activation of the renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in the central or local tissue are the key mechanisms of high blood pressure and its organ damages.

Current guidelines suggest that surgery and aldosterone receptor inhibitors are the only treatment for primary aldosteronism. However, only about 35% of aldosterone tumors and a small number of unilateral adrenal hyperplasia can be treated surgically. More than 60% of primary aldosteronism and bilateral adrenal hyperplasia need long-term oral aldosterone receptor inhibitors. At present, spironolactone is the most commonly used aldosterone receptor inhibitor. Long term use of spironolactone may cause hyperkalemia, hyperplasia of male mammary gland, hairiness of female and other adverse reactions. Therefore, the researchers suggest that partial removal of adrenals can reduce aldosterone level, lower blood pressure and restore potassium metabolism balance.

In patients with primary hyperaldosteronism, the level of aldosterone increases, which can cause vascular endothelial dysfunction, myocardial injury and ventricular fibrosis. The study shows that long-term oral administration of spironolactone can reverse the above cardiovascular damage and correct heart failure. Adrenal artery ablation can reduce aldosterone level, but the long-term effect on cardiovascular system is unknown. In order to confirm the effect of adrenal artery ablation on blood pressure and cardiovascular system, the researchers conducted an open cohort study on patients with primary aldosteronism (including aldosterone, idiopathic aldosteronism and adrenal hyperplasia). To observe the effect of adrenal artery ablation and spironolactone on blood pressure, blood electrolyte, metabolic index, cardiovascular events and cardiovascular death risk in patients with primary aldosteronism, and to explore its efficacy and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

- Primary Aldosteronis diagnosed by increased Renin ratio (ARR) and serum aldosterone levels =15 ng / dl, and confirmed by saline injection test or captopril inhibition test.

- Idiopathic aldosteronism, bilateral adrenal hyperplasia, and unilateral adrenal hyperplasia with no superior secretion confirmed with adrenal CT and adrenal venous blood (AVS).

- The patients was diagnosed with aldosteronoma or unilateral adrenal hyperplasia but refused to surgical excision.

- Signed informed consent and agreed to participate in this study.

Exclusion Criteria:

- Aldosterone cancer.

- Hyperkalemia.

- Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.

- Secondary hypertension except the primary aldosteronism.

- Adrenergic insufficiency.

- Heart failure with NYHA grade ?-? grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.

- Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.

- Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.

- Coagulation dysfunction.

- Pregnant women or lactating women.

- Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.

- Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.

- Allergy or any contraindications for the study drugs, contrast agents and alcohol.

- Refused to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Endovascular chemical Ablation of Adrenal Gland
Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol

Locations

Country Name City State
China The third hospital affiliated to the Army Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Third Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of office systolic and diastolic pressure compared with the baseline between two groups Change of office systolic and diastolic pressure compared with the baseline between the intervention and control group at the end of the study 3 years(End of Trial)
Primary Incidence of major adverse cardiac events (MACE)(%) between two groups Incidence of major adverse cardiac events (MACE)(%)(cardiac death, myocardial infarction and target vessel revascularisation) between two groups at the end of the study 3 years(End of Trial)
Secondary Change of 24-h average systolic blood pressure between two groups Change of 24-h average systolic blood pressure between two groups at end of the study 3 years(End of Trial)
Secondary Change of 24-h average diastolic blood pressure between two groups Change of 24-h average diastolic blood pressure between two groups at end of the study 3 years(End of Trial)
Secondary Change of parameters assessed by echocardiography (IVSd?IVSs?LVPWd, LVPWs, LVEDD, LVEF, LVM) between two groups Change of parameters assessed by echocardiography (IVSd?IVSs?LVPWd, LVPWs, LVEDD, LVEF, LVM) between two groups at end of the study 3 years(End of Trial)
Secondary Change of carotid intima-media thickness assessed by carotid ultrasound between two groups Change of carotid intima-media thickness assessed by carotid ultrasound between two groups at end of the study 3 years(End of Trial)
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A